Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
British Journal of Cancer|November 23, 2021
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trialsDaniel Pietrasz, Shufang Wang-Renault, Julien Taieb, et al.Cancer Letters|July 28, 2026
Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM)Shulin Zhao, Remy Nicolle, Julien Taieb, et al.Scientific Reports|July 18, 2018
Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional surveyJulien Langrand-Escure, Peng Diao, Max-Adrien Garcia, et al.Oncotarget|June 2, 2018
Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarkerAlexis Vallard, Max-Adrien Garcia, Peng Diao, et al.European Journal of Cancer (Oxford, England : 1990)|September 22, 2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised studyJean-Marc Phelip, Véronique Vendrely, Florian Rostain, et al.Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 TrialLaetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.European Journal of Cancer (Oxford, England : 1990)|February 19, 2022
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studiesJulien Edeline, Satoshi Hirano, Aurélie Bertaut, et al.Pageof 10